Chester County News and Community Website
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) reported additional Phase 2 trial data showing higher-dose treatment with its experimental SkinJect therapy produced stronger response rates in patients with nodular …
Medicus Pharma (Nasdaq: MDCX) Advances Lead Skin Cancer Regimen Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) reported additional Phase 2 trial data showing a dose-response relationship for its SkinJect treatment candidate for nodular basal cell carcinoma, with the …
Medicus Pharma Reports Expanded Phase 2 Skin Cancer Trial Data Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) said its chief executive and leadership team met with U.S. lawmakers on Capitol Hill last month to seek support for regulatory and …
Medicus Pharma Meets Lawmakers to Advance SkinJect Program Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) said it submitted an Orphan Drug Designation application to the U.S. Food and Drug Administration for SkinJect (D-MNA) to treat basal cell …
Medicus Pharma Submits Orphan Drug Application for SkinJect Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) said it will present Phase 1 clinical data for its investigational drug Teverelix at the American Association of Clinical Endocrinology Annual Meeting, …
Medicus Pharma to Present Phase 1 Data on Teverelix at AACE 2026 Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) said it will present new Phase 1 clinical data on Teverelix, its investigational long-acting gonadotropin-releasing hormone antagonist, at the American Association of …
Medicus Pharma to Present Phase 1 Teverelix Data at Endocrinology Meeting Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) recently submitted an updated Phase 2 clinical study design to the U.S. Food and Drug Administration for Teverelix, an investigational treatment aimed …
Medicus Submits Phase 2 Study Design for Teverelix to FDA Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) issued a clarification of previously reported Phase 2 trial results for its SkinJect therapy in nodular basal cell carcinoma, the company said.
Medicus Clarifies Phase 2 Results for SkinJect Cancer Therapy Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) said it has submitted an optimized Phase 2 clinical trial protocol to the U.S. Food and Drug Administration for teverelix, an investigational …
Medicus Pharma Submits Phase 2 Protocol for Teverelix to FDA Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) announced it will host a business update webcast on Thursday, March 26, at 11:30 a.m. Eastern time, featuring Dr. Babar K. Rao, …
Medicus Pharma to Host Business Update Call Featuring Clinical Investigator Read More